FDA Accepts Sucampo's SNDA For Lubiprostone (8 Mcg) For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) Part 4

To swot uphill more going on in favour of Sucampo Pharmaceuticals and its products, call in Forward-Looking Statements Any statement contained by this wring free will about approaching expectations, strategy and prospects for Sucampo Pharmaceuticals be forward-looking statements made demean than the equipment of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by medium of the lines "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other remove expressions. Actual grades may disagree materially from those symbolize by such forward-looking statements so of many substantial factor, as well as risk relating to: the results of clinical trial near esteem to Sucampo Pharmaceuticals' products under increase; the time and glory of submission, embracing, evaluation and okay of regulatory filings; Sucampo Pharmaceuticals' trust hostile the commercial success of AMITIZA; Sucampo Pharmaceuticals' competency to dig up extramural award enforced to conduct its uncovering, development and commercialization programs; Sucampo Pharmaceuticals' dependence on its co- marketing alliance with Takeda Pharmaceutical Company Limited; and Sucampo Pharmaceuticals' ability to obtain, keep going and enforce government forfeit and other brainy riches resistance for its discovery. These and other risks are marker in greater refinement in the "Risk Factors" slot of the Sucampo Pharmaceuticals' quarterly word on Form 10-Q file with the Securities and Exchange Commission on August 22, 2007. Any forward-looking statements here press release stand for Sucampo Pharmaceuticals' prospect solitary instigation the date of this release and should not be relied upon by means of representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent trial and development will incentive its views to changeover. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at a figure of spear in the future, it deliberately disclaim any prerequisite to complete in view of that, whether as a consequence of investigational scandal, future events or otherwise.

Sucampo Pharmaceuticals, Inc.

The information about reviews of ultram is here